|
|
|
|
| LEADER |
01000caa a22002652 4500 |
| 001 |
NLM375172572 |
| 003 |
DE-627 |
| 005 |
20240818232157.0 |
| 007 |
cr uuu---uuuuu |
| 008 |
240720s2024 xx |||||o 00| ||eng c |
| 024 |
7 |
|
|a 10.1016/j.clim.2024.110323
|2 doi
|
| 028 |
5 |
2 |
|a pubmed24n1505.xml
|
| 035 |
|
|
|a (DE-627)NLM375172572
|
| 035 |
|
|
|a (NLM)39029640
|
| 035 |
|
|
|a (PII)S1521-6616(24)00432-7
|
| 040 |
|
|
|a DE-627
|b ger
|c DE-627
|e rakwb
|
| 041 |
|
|
|a eng
|
| 100 |
1 |
|
|a van der Mescht, Mieke A
|e verfasserin
|4 aut
|
| 245 |
1 |
0 |
|a Aberrant innate immune profile associated with COVID-19 mortality in Pretoria, South Africa
|
| 264 |
|
1 |
|c 2024
|
| 336 |
|
|
|a Text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a ƒaComputermedien
|b c
|2 rdamedia
|
| 338 |
|
|
|a ƒa Online-Ressource
|b cr
|2 rdacarrier
|
| 500 |
|
|
|a Date Completed 16.08.2024
|
| 500 |
|
|
|a Date Revised 16.08.2024
|
| 500 |
|
|
|a published: Print-Electronic
|
| 500 |
|
|
|a Citation Status MEDLINE
|
| 520 |
|
|
|a Copyright © 2024 The Authors. Published by Elsevier Inc. All rights reserved.
|
| 520 |
|
|
|a The African continent reported the least number of COVID-19 cases and deaths of all the continents, although the exact reasons for this are still unclear. In addition, little is known about the immunological profiles associated with COVID-19 mortality in Africa. The present study compared clinical and immunological parameters, as well as treatment outcomes in patients admitted with COVID-19 in Pretoria, South Africa, to determine if these parameters correlated with mortality in this population. The in-hospital mortality rate for the cohort was 15.79%. The mortality rate in people living with HIV (PLWH) was 10.81% and 17.16% in people without HIV (p = 0.395). No differences in age (p = 0.099), gender (p = 0.127) or comorbidities were found between deceased patients and those who survived. All four of the PLWH who died had a CD4+ T-cell count <200 cells/mm3, a significantly higher HIV viral load than those who survived (p = 0.009), and none were receiving antiretroviral therapy. Seven of 174 (4%) patients had evidence of auto-antibodies neutralizing Type 1 interferons (IFNs). Two of the them died, and their presence was significantly associated with mortality (p = 0.042). In the adjusted model, the only clinical parameters associated with mortality were: higher fraction of inspired oxygen (FiO2) (OR: 3.308, p = 0.011) indicating a greater need for oxygen, high creatinine (OR: 4.424, p = 0.001) and lower platelet counts (OR: 0.203, p = 0.009), possibly secondary to immunothrombosis. Overall, expression of the co-receptor CD86 (p = 0.021) on monocytes and percentages of CD8+ effector memory 2 T-cells (OR: 0.45, p = 0.027) was lower in deceased patients. Decreased CD86 expression impairs the development and survival of effector memory T-cells. Deceased patients had higher concentrations of RANTES (p = 0.003), eotaxin (p = 0.003) and interleukin (IL)-8 (p < 0.001), all involved in the activation and recruitment of innate immune cells. They also had lower concentrations of transforming growth factor (TGF)-β1 (p = 0.40), indicating an impaired anti-inflammatory response. The immunological profile associated with COVID-19 mortality in South Africa points to the role of aberrate innate immune responses
|
| 650 |
|
4 |
|a Journal Article
|
| 650 |
|
4 |
|a CD86
|
| 650 |
|
4 |
|a COVID-19
|
| 650 |
|
4 |
|a Cytokines
|
| 650 |
|
4 |
|a Mortality
|
| 650 |
|
4 |
|a PLWH
|
| 650 |
|
4 |
|a Type 1 IFN antibodies
|
| 700 |
1 |
|
|a de Beer, Zelda
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Steel, Helen C
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Anderson, Ronald
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Masenge, Andries
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Moore, Penny L
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Bastard, Paul
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Casanova, Jean-Laurent
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Abdullah, Fareed
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Ueckermann, Veronica
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Rossouw, Theresa M
|e verfasserin
|4 aut
|
| 773 |
0 |
8 |
|i Enthalten in
|t Clinical immunology (Orlando, Fla.)
|d 1999
|g 266(2024) vom: 17. Aug., Seite 110323
|w (DE-627)NLM098196855
|x 1521-7035
|7 nnns
|
| 773 |
1 |
8 |
|g volume:266
|g year:2024
|g day:17
|g month:08
|g pages:110323
|
| 856 |
4 |
0 |
|u http://dx.doi.org/10.1016/j.clim.2024.110323
|3 Volltext
|
| 912 |
|
|
|a GBV_USEFLAG_A
|
| 912 |
|
|
|a SYSFLAG_A
|
| 912 |
|
|
|a GBV_NLM
|
| 912 |
|
|
|a GBV_ILN_11
|
| 912 |
|
|
|a GBV_ILN_24
|
| 912 |
|
|
|a GBV_ILN_350
|
| 951 |
|
|
|a AR
|
| 952 |
|
|
|d 266
|j 2024
|b 17
|c 08
|h 110323
|